NEW YORK – Binx Health said on Thursday it has received a second 510(k) clearance from the US Food and Drug Administration for the Binx io molecular point-of-care platform for the detection of chlamydia and gonorrhea in male urine specimens.
The agency cleared the system in August 2019 for use with clinician and self-collected vaginal swab specimens.